Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2024-205681

Published: 2024

Journal Articles

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Daniele Cattaneo, Barbara Mora, Cristina Bucelli, Margherita Maffioli, Elena Maria Elli, Giulia Benevolo, Valentina Bellani, Emilia Scalzulli, Filippo Branzanti, Paola Bianchi, Marta Lionetti, Bruno Martino, Umberto Gianelli, Niccolò Bolli, Francesca Palandri, Massimo Breccia, Dario Consonni, Alessandra Iurlo

Blood (2024) 144 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2024-211145

Published: 2024

Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2023-190293

Published: 2023

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Alessandro Andriani, Massimo Breccia, Emilia Scalzulli, Elisabetta Cerchiara, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Roberto Latagliata, Marco Montanaro

Blood (2022) 140 (Supplement 1): 12211–12212.

https://doi.org/10.1182/blood-2022-167056

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Roberto Latagliata, Ida Carmosino, Ambra Di Veroli, Emilia Scalzulli, Gioia Colafigli, Maria Cristina Scamuffa, Alessio Di Prima, Cinzia De Gregoris, Sara Pepe, Marco Mancini, Giulio Trapè, Maurizio Martelli, Robin Foa, Massimo Breccia

Blood (2021) 138 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2021-151220

Published: 2021

Journal Articles

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134496

Published: 2020

Journal Articles

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Serena Rosati, MD, Massimo Breccia, MD, Carmelo Gurnari, MD, Ida Carmosino, Emilia Scalzulli, MD, Enrico Montefusco, Salvatore Perrone, MD, Ombretta Annibali, Vincenza Martini, MD, Giulio Trapè, Malgorzata Monika Trawinska, MD, Clara Minotti, MD, Giuseppe Cimino, MD, Agostino Tafuri, MD, Giuseppe Avvisati, MD, Maria Teresa Voso, MD, Robin Foà, MD, Roberto Latagliata

Blood (2019) 134 (Supplement_1): 3845.

https://doi.org/10.1182/blood-2019-129216

Published: 2019

Journal Articles

Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice

Emilia Scalzulli, MD, Matteo Molica, MD, Alunni Fegatelli Danilo, Lorenzo Rizzo, Roberto Latagliata, Robin Foà, MD, Massimo Breccia, MD

Blood (2018) 132 (Supplement 1): 5518.

https://doi.org/10.1182/blood-2018-99-114880

Published: 2018

Journal Articles

Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice

Matteo Molica, MD, Emilia Scalzulli, MD, Alunni Fegatelli Danilo, Roberto Latagliata, Gioia Colafigli, MD, Lorenzo Rizzo, Daniela Diverio, Robin Foà, MD, Massimo Breccia, MD

Blood (2018) 132 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2018-99-116486

Published: 2018

Journal Articles

Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Daniela De Benedittis, MD, Massimo Breccia, MD, Ida Carmosino, Elena Mariggiò, MD, Matteo Molica, MD, Sara Mohamed, MD, Fulvio Massaro, MD, Maria Lucia De Luca, MD, Emilia Scalzulli, MD, Chiara Lisi, MD, Mauro Passucci, MD, Gioia Colafigli, MD, Maria Giovanna Loglisci, MD, Daniela Diverio, Marco Mancini, Robin Foà, MD, Roberto Latagliata

Blood (2018) 132 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2018-99-117272

Published: 2018

Journal Articles

Does Bone Marrow Fibrosis Play a Role in the Prognostication of Newly Diagnosed Polycythemia Vera Patients?

Matteo Molica, MD, Daniela De Benedictis, MD, Emilia Scalzulli, MD, Ida Carmosino, Laura Cesini, Marta Chisini, MD, Maria Lucia De Luca, MD, Fulvio Massaro, MD, Gioia Colafigli, MD, Marco Mancini, Stefania Trasarti, MD, Massimo Breccia, MD PhD, Robin Foa, MD, Roberto Latagliata

Blood (2017) 130 (Supplement 1): 4184.

https://doi.org/10.1182/blood.V130.Suppl_1.4184.4184

Published: 2017

Journal Articles

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Anna Paola Iori, Karen Brown, David J. Araten, Emilia Scalzulli, Giovanni Fernando Torelli, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foa, MD, Lucio Luzzatto

Blood (2012) 120 (21): 4408.

https://doi.org/10.1182/blood.V120.21.4408.4408

Published: 2012

NARROW

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice

Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice

Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Does Bone Marrow Fibrosis Play a Role in the Prognostication of Newly Diagnosed Polycythemia Vera Patients?

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only